|
Tonix Pharmaceuticals Holding Corp. (TNXP) DCF Valoración
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Tonix Pharmaceuticals Holding Corp. (TNXP) Bundle
Diseñada para la precisión, nuestra calculadora DCF (TNXP) le permite evaluar la valoración de Tonix Pharmaceuticals Holding Corp. utilizando datos financieros del mundo real y ofrece una flexibilidad completa para modificar todos los parámetros esenciales para mejorar las proyecciones.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | 7.8 | 7.8 | 7.8 | 7.8 | 7.8 | 7.8 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -28.8 | -50.5 | -92.3 | -110.8 | -114.1 | 4.7 | 4.7 | 4.7 | 4.7 | 4.7 |
| EBITDA, % | 100 | 100 | 100 | 100 | -1468.7 | 60 | 60 | 60 | 60 | 60 |
| Depreciation | .0 | .0 | .1 | 1.3 | 4.3 | 7.1 | 7.1 | 7.1 | 7.1 | 7.1 |
| Depreciation, % | 100 | 100 | 100 | 100 | 55.24 | 91.05 | 91.05 | 91.05 | 91.05 | 91.05 |
| EBIT | -28.8 | -50.5 | -92.3 | -112.1 | -118.4 | 4.7 | 4.7 | 4.7 | 4.7 | 4.7 |
| EBIT, % | 100 | 100 | 100 | 100 | -1523.94 | 60 | 60 | 60 | 60 | 60 |
| Total Cash | 11.2 | 77.1 | 178.7 | 120.2 | 24.9 | 7.8 | 7.8 | 7.8 | 7.8 | 7.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | 7.6 | 7.7 | .0 | 4.6 | 7.1 | 7.1 | 7.1 | 7.1 | 7.1 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 59.09 | 91.82 | 91.82 | 91.82 | 91.82 | 91.82 |
| Inventories | -1.0 | -7.6 | -7.7 | -8.0 | 14.1 | 7.8 | 7.8 | 7.8 | 7.8 | 7.8 |
| Inventories, % | 100 | 100 | 100 | 100 | 182.12 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 3.1 | 4.6 | 13.3 | 8.1 | 3.8 | 7.0 | 7.0 | 7.0 | 7.0 | 7.0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 48.69 | 89.74 | 89.74 | 89.74 | 89.74 | 89.74 |
| Capital Expenditure | .0 | -8.6 | -35.3 | -48.1 | -7.9 | -1.6 | -1.6 | -1.6 | -1.6 | -1.6 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | -101.63 | -20 | -20 | -20 | -20 | -20 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -31.3 | -52.2 | -92.3 | -118.9 | -118.4 | 4.7 | 4.7 | 4.7 | 4.7 | 4.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -27.2 | -60.2 | -118.9 | -162.9 | -153.1 | 17.2 | 10.2 | 10.2 | 10.2 | 10.2 |
| WACC, % | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 48.3 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 10 | |||||||||
| Terminal Value | 209 | |||||||||
| Present Terminal Value | 149 | |||||||||
| Enterprise Value | 198 | |||||||||
| Net Debt | -15 | |||||||||
| Equity Value | 213 | |||||||||
| Diluted Shares Outstanding, MM | 1 | |||||||||
| Equity Value Per Share | 399.38 |
What You Will Get
- Real TNXP Financial Data: Pre-filled with Tonix Pharmaceuticals’ historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Tonix Pharmaceuticals’ intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive TNXP Data: Pre-filled with Tonix Pharmaceuticals' historical financials and future projections.
- Fully Adjustable Inputs: Modify revenue growth, profit margins, WACC, tax rates, and capital expenditures as needed.
- Dynamic Valuation Model: Instant updates to Net Present Value (NPV) and intrinsic value based on your customized inputs.
- Scenario Analysis: Develop various forecast scenarios to explore different valuation possibilities.
- User-Friendly Interface: Intuitive, organized, and suitable for both professionals and novices.
How It Works
- Step 1: Download the prebuilt Excel template featuring Tonix Pharmaceuticals' data.
- Step 2: Navigate through the pre-filled sheets to grasp the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly view recalculated results, including Tonix Pharmaceuticals' intrinsic value.
- Step 5: Make informed investment decisions or create reports based on the outputs.
Why Choose This Calculator for Tonix Pharmaceuticals (TNXP)?
- Designed for Industry Experts: A sophisticated tool favored by analysts, CFOs, and healthcare consultants.
- Accurate Financial Data: Tonix Pharmaceuticals' historical and projected financials preloaded for precision.
- Comprehensive Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Insightful Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly Interface: Step-by-step guidance to navigate through the calculation process.
Who Should Use Tonix Pharmaceuticals Holding Corp. (TNXP)?
- Investors: Gain insights into the pharmaceutical sector with a reliable research platform.
- Financial Analysts: Streamline your analysis with comprehensive data on TNXP's market performance.
- Consultants: Easily modify reports and presentations to showcase TNXP's potential to clients.
- Pharmaceutical Enthusiasts: Enhance your knowledge of drug development and market trends through TNXP's case studies.
- Educators and Students: Utilize it as a resource for learning about the pharmaceutical industry and investment strategies.
What the Template Contains
- Historical Data: Includes Tonix Pharmaceuticals' past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Tonix Pharmaceuticals' intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Tonix Pharmaceuticals' financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.